Cancer treatment is in the need of selective drugs that can interfere specifically with signalling pathways affected during the carcinogenic process. Identification of new potential molecular targets is the key event in the design of new anticancer strategies. Once identified, attempts for the generation of specific molecules to regulate their function can be achieved. The relevance of deregulation of choline kinase (ChoK, E.C. 2.7.1.32) in oncogene-driven cell transformation has been previously demonstrated. Here we provide strong evidence that MN58b, a selective inhibitor of ChoK, is rather specific to this enzyme, with no effect on a variety of oncogene-activated signalling pathways involved in the regulation of cell proliferation. MN58b does not affect MAPKs, PI3K, and other enzymes involved in the regulation of phospholipid metabolism such as phospholipases C, D, and A2, CTP:phosphocholine cytidylyltransferase, or diacylglycerol choline-phosphotransferase. Consistent with this specificity, ectopic expression of ChoK resulted in resistance to its inhibitor. Finally, nontransformed cells were able to resume cell proliferation after removal of the drug, while transformed cells were irreversibly affected. These results indicate that inhibition of ChoK is a rather specific strategy for the cytotoxic treatment of transformed cells.
Introduction
Proliferating cells must comply with a series of events leading to duplication of their structural components. These events occur in a strict temporal order. Membrane phospholipids are placed among the most critical components that need to be duplicated. Thus, accumulation of phosphatidylcholine (PC), which is the most abundant membrane phospholipid, is a typical and periodic event that is coordinated in the cell cycle. Net PC accumulation (membrane phospholipid doubling) occurs as cells enter the S phase and results from an interaction between cell cycle-dependent oscillations in the rates of PC biosynthesis and degradation (Lykidis and Jackowski, 2001) . Two candidate enzymes have been postulated as the rate-controlling step in PC biosynthesis, depending on the conditions: CTP : phosphocholine cytidylyltransferase (CT) and choline kinase (ChoK). Both enzymes participate in the Kennedy pathway, responsible for the de novo synthesis of PC. CT activity, the most prominent candidate so far to be the real rate-limiting step, is regulated by cell cycle-dependent phosphorylation. CT activity increases in early G1 and then decreases steadily as the cells progress through late G1, S, and G2/M, reflecting the elevated phosphorylation state of the protein (Jackowski, 1994; Lykidis and Jackowski, 2001) . There is also evidence suggesting that ChoK may be a ratelimiting step. Indeed, hormones and growth factors induce the transient activation of ChoK, most likely via transcriptional regulation (Warden and Friedkin, 1985; Ko et al., 1986; Uchida, 1996) . Furthermore, yeast ChoK is phosphorylated and upregulated by cAMP-dependent kinase (PKA), suggesting its posttranscriptional regulation (Kim and Carman, 1999) . These results could also be extrapolated to the regulation of mammalian ChoK (Wieprecht et al., 1994) . Phospholipase A2 (PLA2) and PLD mediate the degradation of PC and promote the renovation of PC in the plasma membrane. This binary system of regulated synthesis by ChoK and CT, and degradation by phospholipases, is the main mechanism for maintaining PC homeostasis in the cell (Baburina and Jackowski, 1999) .
We have previously demonstrated that inhibition of ChoK by hemicholinium-3 interferes with the mitogenic action of growth factors such as platelet-derived growth factor (PDGF) or fibroblast growth factor (FGF) in mouse fibroblasts (Cuadrado et al., 1993; Jime´nez et al., 1995; Herna´ndez-Alcoceba et al., 1997) . However, there is evidence that HC-3 may not be specific for ChoK interfering with other signalling pathways (Lacal, 2001) . Furthermore, the relevance of PCho production is supported by additional experiments. Thus, the exogenous addition of PCho to the culture medium induces the G1-S transition in murine fibroblasts (Cuadrado et al., 1993; Jime´nez et al., 1995; Herna´ndez-Alcoceba et al., 1997) , and cooperates with other mitogens and related compounds for mitogenic activity (Kiss and Chung, 1996; Chung et al., 1997 Chung et al., , 2000 .
ras-Transformed cells show increased ChoK activity and higher PCho levels than their parental cell lines (Lacal et al., 1987; Macara, 1989; Teegarden et al., 1990) . The intracellular levels of PCho are increased not only in stably transfected cells (Lacal et al., 1987; Macara, 1989; Herna´ndez-Alcoceba et al., 1997) but also in transient expression systems (Lacal, 1990; Ratmant and Kent, 1995) . PC degradation and synthesis are activated in ras-transformed (Yang et al., 1990a, b; Oikawa et al., 1991) and src-transformed cells (Yang et al., 1990b) , suggesting a role for the Kennedy pathway in cell division. Furthermore, nuclear magnetic resonance (NMR) spectroscopy demonstrated a gradual increase in both PCho and total choline-containing metabolite levels as cells progressed from normal to malignant phenotype (tumor-derived cells4oncogene-transformed4immortalized4normal). A glycerophosphocholine (GPC) to PCho switch appeared to be an early phenotypic change during carcinogenesis, independent of cell-doubling time and without differences in high-energy phosphates, rates of glucose consumption and aerobic glycolysis (Ting et al., 1996; Aboagye and Bhujwalla, 1999) . Additional NMR studies also find high levels of phosphomonoesters (PCho and/or PEtn) in tumors when compared to the corresponding normal tissues (de Certaines et al., 1993; Smith et al., 1993; Bhakoo et al., 1996) . Finally, increased ChoK activity has been demonstrated in human tumors (Ramirez de Molina et al., 2002a, c) , and a functional relationship between Ras proteins and ChoK has been established (Ramirez de Molina et al., 2002b) .
All these observations have justified the consideration of ChoK as a potential target for the development of anticancer drugs. Our group has used the structure of HC-3, a choline homologue and inhibitor of ChoK (Ansell and Spanner, 1974; Cannon, 1994) , as a model for further development of more active and specific ChoK inhibitors (Jime´nez et al., 1995; Herna´ndez-Alcoceba et al., 1997 Lacal, 2001) . These compounds improve the inhibitory activity against ChoK, and showed antimitogenic activity in vitro (Herna´ndez-Alcoceba et al., 1997) as well as antitumoral activity in vivo (Herna´ndez-Alcoceba et al., 1999) , without the characteristic neurological toxicity of HC-3 (Cannon, 1994; Herna´ndez-Alcoceba et al., 1999; Lacal, 2001 ). Here we present evidence for the selective and differential effect of MN58b, a newly developed ChoK inhibitor, against transformed cells versus nontransformed cells. MN58b has a rather selective mechanism of action towards ChoK, demonstrating that ChoK inhibition is a valid strategy for the design of new antitumoral agents.
Results

Inhibition of ChoK induces specific effects in transformed cells
We have previously reported the generation of several novel ChoK inhibitors with both antiproliferative activity in vitro and antitumoral activity in vivo (Herna´ndez-Alcoceba et al., 1999) . Among these, MN58b is one of the most potent and specific inhibitors of ChoK both in vitro and in vivo (Herna´ndez-Alcoceba et al., 1997 . We have investigated further the specificity of these new ChoK inhibitors, using MN58b as a model.
ras-Transformed cells show higher PCho levels than their normal counterparts as a consequence of increased ChoK activity (Lacal et al., 1987; Macara, 1989; Lacal, 1990; Teegarden et al., 1990; Cuadrado et al., 1993; Herna´ndez-Alcoceba et al., 1997; Momchilova et al., 1999) . If PCho is a requirement for cell proliferation of transformed cells, then these cells may be more sensitive to the inhibition of ChoK. Therefore, we investigated the effect of ChoK inhibitors in oncogene-transformed cells. As controls, the parental NIH3T3 cells as well as NIH3T3 cells transformed by the v-fos oncogene were used. Both ras-and src-transformed cells showed increased ChoK activity, while the fos-transformed cells showed similar levels to that of control, nontransformed NIH3T3 cells (Herna´ndez-Alcoceba et al., 1997). Cells transformed by human H-ras (Harvey-ras) and the src oncogenes, that show increased ChoK activity, were more sensitive to the inhibitory action of MN58b than the parental cells or those overexpressing fos oncogene (Table 1 ). In fact, fos-expressing cells behaved as the parental cells in response to MN58b treatment. Similar results were observed when MN82, another ChoK inhibitor of the same family (Herna´ndez-Alcoceba et al., 1999) , was used (data not shown). Thus, cell transformation associated with increased ChoK activity renders cells more sensitive to the antiproliferative action of ChoK inhibitors. These results also suggest that ChoK inhibitors may interfere with signalling pathways required for the maintenance of the transformed phenotype. 
Specificity of ChoK inhibitors in normal proliferating cells
The inhibitory effects on cell proliferation by ChoK inhibitors may result from the specific inhibitory effect towards PCho synthesis or due to interference with other nonspecific signalling pathways relevant for cell proliferation in the transformed cells. Thus, we aimed at investigating the specificity of the newly developed ChoK inhibitors. Tumor-derived cell lines may carry a variety of genetic alterations that may not have been identified. Thus, it is impossible to conclude whether a specific inhibitor functions through a particular target since additional, unknown components, may interfere with the results. To analyse for the specificity of ChoK inhibitors, we used murine NIH3T3 cells genetically engineered as a better controlled approach.
First, putative nonspecific toxic effects were studied by determining the inhibitory effect on DNA synthesis under different proliferating conditions. When NIH3T3 cells were stimulated by growth factors, a strong reduction in the rate of DNA synthesis was observed in the presence of MN58b (Figure 1 ). This inhibitory effect was dependent upon the specific stimulus used. Thus, when cells were treated with PDGF, the MN58b concentration required to achieve 50% inhibition in DNA synthesis was 8.7 mM. This was increased to 17.4 mM when the mitotic signalling was complemented with insulin, or to 23 mM when cells were stimulated by 10% NCS. By contrast, when cells were incubated in the presence of 20% fetal bovine serum (FBS), no inhibition was observed by MN58b. These results suggest that a proper combination of growth stimuli overruled ChoK inhibition by MN58b, and provide further support to the lack of unspecific toxicity as their mechanism of action.
Effects of MN58b on alternative signalling and metabolic pathways
Next, the possible interference of ChoK inhibitors with relevant signalling enzymes activated by Ras proteins such as ERK (Warne et al., 1993) or PI3K (RodriguezViciana et al., 1994) was investigated. Quiescent cells were stimulated with PDGF in the presence or absence of MN58b, and ERK activation determined by Western blot using a specific antibody against the phosphorylated ERK proteins. As shown in Figure 2 , no effect on either ERK kinase was observed even at very high concentrations of MN58b.
PI3K activation was determined by two alternative methods. First, an indirect approach was followed by determining the activation of Akt, which reflects the activation of PI3K (Franke et al., 1995 . Cells were stimulated by PDGF in the presence or absence of MN58b. Samples were Western blotted with an anti-phospho-Akt specific antibody. Finally, cells were stimulated by PDGF, and then PI3K immunoprecipitated using an antiphosphotyrosine antibody. Immunoprecipitates were then assayed for PI3K activity according to the standard protocol, as described under Materials and methods, in the presence or absence of MN58b. As shown in Figure 2 , MN58b treatment had no effect on PI3K activity, indicating that the ChoK inhibitor does not interfere with PI3K activation. Furthermore, these results also demonstrate that MN58b does not affect the interaction of PDGF with its receptor, the activation process of the receptor (including the enzymatic activity of the PDGF receptor), or the interaction of the activated receptor with PI3K.
Next, the effect of MN58b on phospholipid metabolism was also investigated. First, the possible interference of MN58b with choline transport was determined. As shown in Figure 3a , MN58b effectively interfered with choline uptake, with more than 90% inhibition at 30 min treatment. HC-3 was able to interfere with choline uptake but much less efficiently with 33% inhibition after 30 min treatment. This further increased the ability of MN58b to affect PCho synthesis. The activities of CT and PLD, the two enzymes mostly related to ChoK and coresponsible for the regulation of PC levels, were next studied. PLD activity was determined by its specific transphosphatidylation activity after stimulation with phorbol esters. CT was analysed by determining the production of CDP-choline using radiolabelled choline as probe. As shown in Figure 3 , no inhibitory effect on PLD or CT was 
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Choline kinase as an anticancer drug target A Rodríguez-González et al observed, an indication that even very close enzymes to ChoK involved in phospholipid metabolism were not affected by MN58b.
The effect of MN58b treatment on the steady-state levels of relevant phospholipids such as PC, lysophosphatidylcholine (LPC) and sphingomyelin (SM) was also investigated. To that end, cells were labelled with either choline or glycerol for 48 h and then treated with MN58b for 24 h. The levels of PC, Lyso-PC and SM were then analysed. As shown in Figure 4 , no effect on the metabolic pathways of these lipids was observed. Similar results were observed for PC levels when the labelling used was glycerol (data not shown). By contrast, MN58b induced a depletion of the radioactive PCho pool under similar conditions, an indication of a strong inhibition of the de novo PCho production. Thus, 
MN58b did not affect directly the synthesis or degradation of the most important phospholipids related to choline metabolism. These results indicate that signalling pathways such as ERKs or PI3K, and enzymes involved in phospholipid metabolism related to PC, are not the targets for ChoK inhibitors.
Ectopic expression of ChoK induces resistance to MN58b
To further support the specificity towards ChoK of MN58b and its effects on tumor cells, the murine ChoK gene was placed in a retroviral vector and transfected into NIH3T3 cells. Several clones that showed increased ChoK activity were isolated (Figure 5 ), and two of these cell lines (T-Mar 9, T-Mar 11) were selected for further characterization. A twofold increase in ChoK activity was achieved in these particular cell lines, but no change in morphology or tumorigenic capacity was observed (data not shown). Surprisingly, overexpression of ChoK in stably transfected cells was not enough to increase the intracellular PCho levels (Figure 5b) , suggesting a posttranscriptional regulation of ChoK activity. However, as shown in Table 2 , nontransformed cells overexpressing ChoK were less sensitive to MN58b than the parental NIH3T3 cells. IC 50 were increased by 2.4-4.9-fold at 96 h of treatment. Thus, a clear displacement of sensitivity was observed, indicating that higher levels of ChoK expression in nontumorigenic cells induced some increase of resistance to the treatment, further supporting the specificity of ChoK inhibition as the basis for the antiproliferative effect of MN58b. Chung et al. (2000) reported increased levels of up to 40-fold ChoK activity into NIH3T3 cells which correlated with an increase of 4-12-fold in the levels of intracellular PCho determined by NMR studies. Thus, we investigated whether our low levels of ChoK expression were due to cell specificity. To that end, we attempted to develop stable cell lines with higher expression levels of ChoK. We used not only NIH 3T3 but also MDCK and HEK 293T cell lines. In transient transfection experiments, we observed up to fivefold increase in ChoK expression (data not shown). However, when cells were stable transfected, overexpression of ChoK decreased to twofold increase (data not shown). The reason for the discrepancy with Chung et al. (2000) is unknown, but it is important to note that we use the murine ChoK gene in our experiments, while Chung et al. (2000) used the human ChoK gene. The use of different plasmids to drive ChoK expression could also account for it. It is important to note that ras-and src-transformed cells showed also a twofold increase in ChoK, similar to that observed in all cell lines investigated in our study. These are the best conditions for a comparative study between transformed and 
Inhibition of ChoK results in a reversible blockage of proliferation
The goal for all anticancer drugs is to reach high specificity against tumoral cells, leaving normal cells unaffected. We next investigated the possibility of reconstituting normal proliferation rates in NIH3T3 cells, after treatment with MN58b. To that end, NIH3T3 cells were treated for 24, 48 or 72 h and the drug removed, and cells incubated under normal conditions. As shown in Figure 6 , a total recovery of the proliferation rates in NIH3T3 cells was observed after the withdrawal of the ChoK inhibitor. This result indicates the absence of nonspecific toxicity or irreversible damage by the ChoK inhibitor in this cell line that induces cell arrest but not apoptosis (Figure 6e ). By contrast, when ras-transformed cells were treated for 24, 48 or 72 h in a similar manner, the recovery was not complete, indicating that some degree or specific irreversible damage took place. This reflects the effect on proliferation of ChoK inhibitors, which was higher in ras-and src-transformed cells than in their parental NIH3T3 cells (Table 1) . Reversibility of the cytostatic effect on nontransformed NIH3T3 cells was observed up to 144 h (6 days) of treatment with 40 mM (data not shown).
Discussion
Malignant cells are characterized by a number of alterations in signal transduction pathways that control proliferation, differentiation and apoptosis (Cantley et al., 1991; Lewin, 1991) . The identification of these aberrant processes may allow the development of specific chemotherapeutic interventions that will be able to restore those normal regulatory signalling pathways lost during the carcinogenic process, or to selectively destroy the transformed cells (Gibbs and Oliff, 1994; Friend and Oliff, 1998) . Many of the currently used antitumoral agents owe their useful but limited activity to either inhibition of enzymes involved in DNA synthesis, or direct chemical DNA damage. Also, inhibition of the mechanisms of cell division, often at the level of microtubule function, or disruption of signalling and transduction pathways have been explored successfully (Gibbs and Oliff, 1994; . In most of the cases, there is no difference among transformed cells and nontransformed cells as to what leads to the generation of unspecific toxicity which limits their therapeutic margin. In addition, some chemotherapeutic agents cause serious damage to the patient. Therefore, the need to look for new cancer drug targets with improved selectivity against cancer cells is obvious.
Recent evidence proves that it is possible to produce inhibitors or activators of crucial biochemical processes. However, the same or similar transduction pathways may be essential for normal cell growth and homeostasis . Thus, disrupting some specific metabolic pathways that play a role in Generation of PCho through ChoK may have important signalling functions since it is an absolute requirement for cell growth in response to specific growth factors (Figure 1 ). Here we have provided strong evidence that specific interference of ChoK-dependent generation of PCho has a drastic effect on cell proliferation to both transformed and nontransformed cells. Moreover, we have observed that nontransformed cells do not respond to ChoK inhibitors, as do the oncogene-transformed cells. Thus, while nontransformed cells are arrested under ChoK blockage and fully restored proliferation after removal of treatment, transformed cells do not recover from treatment, a demonstration of some specific irreversible damage. Thus, the experiments shown in this study indicates that ChoK inhibitors are more selective for oncogenetransformed cells. An interesting observation is that increased ChoK activity in ras-transformed cells seems to provide higher sensitivity towards treatment with ChoK inhibitors, while a similar increase in ChoK activity in nontransformed cells renders these cells resistant to the treatment. Furthermore, expression of ChoK is not sufficient to acquire the transforming phenotype. At last, inhibition of ChoK in a nontransformed context is reversible, while transformed cells undergo irreversible damage. The nature of this effect is still not fully understood, but suggests that, as a consequence of treatment with ChoK inhibitors, some specific metabolic alteration in transformed cells displaces the balance of choline and its derivatives to the generation of an intrinsic toxic response. By contrast, normal cells do generate a nontoxic signal able to stop cell proliferation in a reversible manner.
We have attempted to determine the underlying mechanisms on the basis of this specificity. Our results indicate that the specific response among nontransformed and transformed cells resides in the inhibitory effect on ChoK. The drastic effect of ChoK inhibitors in reducing PCho levels in treated cells, along with the lower effect in cells that ectopically express ChoK, indicates a rather specific inhibition of ChoK. This statement is further supported by the lack of an effect on other signalling and metabolic pathways, even those closely related to ChoK. Thus, the interaction of growth factors with their receptors, the kinase activity of activated receptors and the subsequent activation of the ERKs, PI3K, as well as phospholipid pathways are not affected by ChoK inhibitors. Furthermore, the lack of any effect on the enzymes involved in PC homeostasis such as CT, CPT and PLD, or the synthesis of the major membrane phospholipids, provides strong evidence for the specificity of ChoK inhibitors to their target. Finally, nonspecific toxic effects can be ruled out since addition of 20% FBS overcomes the inhibitory effects on cell proliferation. This observation suggests that depletion of PCho, and its concomitant arrest in G1, could be overcome by additional mitogenic or metabolic signals, and that ChoK inhibition is rather specific to defined signalling pathways. Further evidence that ChoK inhibitors have no unspecific toxic effects on the cells is the lack of induction of apoptosis in NIH3T3 cells and its full recovery from treatments as severe as 6 days (data not shown). Furthermore, although 20% FBS overcomes the blockage of ChoK inhibition in NIH3T3 cells, MN58b has antitumoral activity in vivo (Herna´ndez-Alcoceba et al., 1999), ruling out the possible interference of serum with the antitumoral activity of ChoK inhibitors. Thus, this could be explained if, in nontransformed cells, saturation of mitogenic signalling bypasses the blockage of MN58b in the transition from G1 to S phase. This may take place because mitogenic signalling may be redundant under saturating stimulation. Bypass of PCho-dependent signalling blockage may translate into a metabolic disruption. Therefore, the effect of 20% FBS indicates the absence of nonspecific cytotoxic effect by ChoK inhibitors.
The results presented here demonstrate that inhibition of ChoK defines the basis for the differential effect in normal and transformed cells by ChoK inhibitors. Therefore, we provide strong evidence that this strategy may be useful in human therapy. In addition, all these results provide further support to the possible dual function of PCho as a PC precursor and as a mitotic signalling molecule.
Materials and methods
Cell culture and reagents
All cell lines used in this study were maintained under standard conditions of temperature (371C), humidity (95%) and carbon dioxide (5%). The culture medium for NIH cell line was DMEM supplemented with 10% new calf serum (NCS) (Life Technologies, Grand Island, NY, USA). Cell lines NIH (ATCC CRL 1658, mouse fibroblast) and their derivatives, Harvey-ras, Kirsten-ras and N-ras transformed (LP8-3), ChoK-transfected (T-Mar 9/11), v-src and v-fos, were grown in DMEM supplemented with 10% newborn calf serum (Gibco, Grand Island, NY, USA).
Analysis of ChoK activity in whole cells
Cells were incubated for 2 days and labelled during 24 h with [methyl-14 C]choline chloride from ICN pharmaceuticals (Inc.). Then they were rinsed in ice-cold TD buffer (137 mM NaCl, 5 mM KCl and 20 mM Tris pH ¼ 7.4) and fixed with 16% icecold trichloroacetic acid. Trichloroacetic acid-soluble material containing Cho, PCho and CDP-Cho was washed three times with four volumes of diethylether, dried under vacuum, and resuspended in water. Samples were resolved by TLC on 60 A (Whatman, Clifton, NJ, USA), using as liquid phase 0.9% NaCl : methanol : ammonium hydroxide (50 : 70 : 5; v/v/v). Radioactivity corresponding to Pcho was automatically quantified by an electronic radiography system (Instantimager; Packard, Meriden, CT, USA).
Cytometry
Adherent cell lines were seeded at a density of 40 Â 10 3 cells/ well, and treated 24 h later. They were trypsinized and spun 400 g, diluted in 1 ml PBS, and fixed by adding 9 ml of 70% ethanol. Cells were harvested by centrifugation of 10 min at 400 g. The samples were resuspended in 1 ml PBS (2.5 mM C 6 H 5 Na 3 O 7 , 0.01% TX 100, 20 mg propidium iodide).
Mitogenic assays
DNA synthesis NIH cells were seed at a density of 3 Â 10 4 / well and processed as described (Herna´ndez-Alcoceba et al., 1997) . At 3 or 4 h before processing, 1 mCi/ml methyl-[3H]thymidine was added. Afterwards, we rinsed with TD before fixing with 16% TCA.
Cell proliferation assays All adherent cell lines were seeded at 20 Â 10 3 cells/well, and incubated for 24 h. Cells were then treated as previously reported (Gillies et al., 1986) .
Analysis of PLD activity PLD activity was measured by its transphosphatidylating property, as previously described in detail (Carnero et al., 1994; Herna´ndez-Alcoceba et al., 1997) .
Western blot analysis
Cells were incubated with ChoK inhibitors prior to stimulation for 4 h, and processed as previously described 
Analysis of lipid metabolism
NIH cells (typically 10 4 /well) were seeded on six-well plates and incubated for 2 days in the presence of 1 mCi/ml [ 14 C]glycerol or methyl [C 14 ]-choline. Cells were then treated without replacing the labelling medium with the indicated ChoK inhibitors during 24 h. Cells were harvested in 1 ml of methanol. Then lipids were extracted by a chloroform : water solution (2 : 1, v:v) and dried in a concentrator under N 2 flow at 371C. Samples were solved in chloroform and lipids separated by TLC using a mixture of chloroform : acetone : methanol : acetic acid : water as liquid phase (40 : 15 : 13 : 12 : 7) (V : V : V : V : V). Quantification of the resolved lipids was carried out by Instantimager.
Analysis of PI3-K activity PI3-K activity measurement was carried out as previously described in detail (Herna´ndez-Alcoceba et al., 1997) . Cells were grown to confluence in dishes of 10 cm diameter, and serum-starved for 12-24 h and treated with the ChoK inhibitor 4 h prior to stimulation. Then, the medium was replaced with 2 ml of DMEM containing 20 ng/ml PDGF-BB and the indicated treatment. Stimulation proceeded for 10 min at 371C. Cells were then washed with cold TD buffer, rinsed with buffer A (137 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 1 mM CaCl 2 , 1 mM Na 3 VO 4 ), and lysed in buffer A containing 1% NP40 and 1 mM PMSF at 41C for 20 min. The insoluble material was removed by centrifugation at 10 000 g for 15 min. The supernatants were assayed for estimation of total cell protein and equal amounts of lysates were incubated with 10 ml of a mouse monoclonal anti-phosphotyrosine antibody (SantaCruz) overnight at 41C. Sepharose C14B protein G (Sigma) was added and incubation proceeded for two additional hours. Immunoprecipitates were collected and washed three times with 1% NP40, 1 mM Na 3 VO 4 in TD buffer, twice with 100 mM Tris-HCl, pH 7.5, 500 mM LiCl and twice with 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA. Immunoprecipitates were then assayed for phosphatidylinositol (PI) phosphorylation activity, as previously described (Jime´nez et al., 1995) .
Analysis of ChoK
Lysed cells (50 mg) were incubated 30 min at 371C in a buffer containing 100 mM Tris pH 8, 100 mM MgCl 2 , 10 mM ATP and 200 mM methyl [C 14 ]-choline (55 mCi/nmol, 2 mCi/ml) in a final volume of 50 ml. The reaction was stopped in ice by adding 10 ml 500 mM EDTA. A volume of 30 ml of every sample were resolved in these layer chromatography plates (LK6D Silica gel 60 a , Whatman Inc., NJ, USA) using 0.9% NaCl : methanol : ammonium hydroxide (50 : 70 : 5; V : V : V) as liquid phase. Quantification of the resolved lipids was carried out by Instantimager.
